Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
WINREVAIR is a breakthrough biologic for this rare, progressive disease
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
The validations confirm the completion of the applications and commence the scientific review process
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
